Brokerages Set Haleon plc (NYSE:HLN) Price Target at $10.95

Shares of Haleon plc (NYSE:HLN) have been given a consensus recommendation of “Buy” by the six ratings firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $10.95.

A number of analysts recently issued reports on HLN shares. The Goldman Sachs Group lowered shares of Haleon from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 6th. UBS Group raised Haleon to a “strong-buy” rating in a research report on Tuesday, October 1st. Morgan Stanley increased their target price on Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a research report on Friday, September 20th. Finally, Berenberg Bank initiated coverage on Haleon in a report on Tuesday, August 6th. They issued a “buy” rating for the company.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HLN. Fortitude Family Office LLC acquired a new stake in Haleon during the third quarter worth about $28,000. Toronto Dominion Bank increased its position in Haleon by 3,470.0% during the 3rd quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock worth $38,000 after purchasing an additional 3,470 shares in the last quarter. Cultivar Capital Inc. acquired a new stake in Haleon during the 2nd quarter worth approximately $40,000. Prospera Private Wealth LLC purchased a new position in Haleon in the third quarter valued at approximately $57,000. Finally, Hexagon Capital Partners LLC lifted its position in Haleon by 66.6% during the second quarter. Hexagon Capital Partners LLC now owns 6,695 shares of the company’s stock valued at $55,000 after buying an additional 2,677 shares in the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Price Performance

Haleon stock opened at $9.72 on Friday. The stock has a market capitalization of $44.00 billion, a P/E ratio of 28.59, a P/E/G ratio of 2.89 and a beta of 0.30. Haleon has a 12-month low of $7.89 and a 12-month high of $10.80. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. The firm’s 50-day moving average is $9.95 and its two-hundred day moving average is $9.41.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.